Jennifer Schmitke
Direttore operativo presso IMV INC.
Posizioni attive di Jennifer Schmitke
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| IMV INC. | Direttore operativo | - | - |
Storia della carriera di Jennifer Schmitke
Precedenti posizioni note di Jennifer Schmitke
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| EPIZYME, INC. | Corporate Officer/Principal | - | 01/04/2022 |
| BIOGEN INC. | Direttore/Membro del Consiglio | - | - |
| OMEGA THERAPEUTICS, INC. | Corporate Officer/Principal | - | - |
| MAGENTA THERAPEUTICS | Corporate Officer/Principal | - | - |
Formazione di Jennifer Schmitke
| Queen's University | Undergraduate Degree |
| Massachusetts Institute of Technology | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 6 |
| Canada | 3 |
Posizioni
| Corporate Officer/Principal | 3 |
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
Settori
| Health Technology | 6 |
| Consumer Services | 2 |
| Finance | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| OMEGA THERAPEUTICS, INC. | Health Technology |
| IMV INC. | Health Technology |
| BIOGEN INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Jennifer Schmitke
- Esperienza
